KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Interest Expenses (2020 - 2025)

Historic Interest Expenses for Alnylam Pharmaceuticals (ALNY) over the last 6 years, with Q4 2025 value amounting to $65.4 million.

  • Alnylam Pharmaceuticals' Interest Expenses rose 6781.71% to $65.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $208.4 million, marking a year-over-year increase of 4687.43%. This contributed to the annual value of $252.6 million for FY2025, which is 7808.44% up from last year.
  • According to the latest figures from Q4 2025, Alnylam Pharmaceuticals' Interest Expenses is $65.4 million, which was up 6781.71% from $44.4 million recorded in Q3 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Interest Expenses registered a high of $65.4 million during Q4 2025, and its lowest value of $29.0 million during Q1 2023.
  • In the last 5 years, Alnylam Pharmaceuticals' Interest Expenses had a median value of $36.0 million in 2021 and averaged $38.5 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first tumbled by 3164.86% in 2023, then soared by 6781.71% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Interest Expenses (Quarter) stood at $36.8 million in 2021, then decreased by 18.75% to $29.9 million in 2022, then increased by 4.76% to $31.3 million in 2023, then rose by 24.36% to $39.0 million in 2024, then skyrocketed by 67.82% to $65.4 million in 2025.
  • Its Interest Expenses stands at $65.4 million for Q4 2025, versus $44.4 million for Q3 2025 and $40.2 million for Q2 2025.